Technologies Available for Licensing

For Licensing Opportunities, please contact the ORTA at USArmy.Detrick.MEDCOM-USAMRMC.List.ORTA@health.mil



COMPOSITIONS AND METHODS FOR SILENCING GENES INVOLVED IN HEMORRHAGIC FEVER

The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA (e.g., dsRNA such as siRNA) that target Lassa virus (LASV) or tissue factor (TF) gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles (e.g., for treating hemorraghic fever).


Docket:RIID 2012-01

Publication/Issued No.:8,455,455

Publication/Issue Date:2013-06-04

Categories: Vaccine

More Detail:Visit USPTO.GOVExternal link

Lab:RIID

Inventor(s):ROBBINS, ET AL


For Licensing Opportunities, please contact the ORTA at USArmy.Detrick.MEDCOM-USAMRMC.List.ORTA@health.mil
 

Last Modified Date: 25 Jul 2023

This Web site provides an introduction to the Office of Research and Technology Applications (ORTA) and contains official Government information.

Its use is intended for members of the general public, news media and Military Health System beneficiaries.

Please address questions or concerns about this Web site to the USAMRDC Public Affairs Office at:
USArmy.Detrick.MEDCOM-USAMRMC.List.ORTA@health.mil or by telephone at (301)619-2736.